Cellestia Biotech AG is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus. The ...

- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy ...

iTeos has developed a novel small molecule inhibiting PTPN1/2. The PTPN1/2 phosphatases are negative regulators of cytokine signaling pathways and T cell receptor signaling. Inhibiting or depleting ...

A new article published in Acta Pharmaceutica Sinica B discusses aureane-type sesquiterpene tetraketides as a novel class of immunomodulators with interleukin-17A inhibitory activity. Interleukin (IL) ...

Protein folding diseases, from Alzheimer's to Gaucher's, may one day be treated by a unique class of protein corrector molecules that are already helping manage cystic fibrosis. Protein misfolding is ...

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes ...

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and ...

This week, host Brittany Luse chats with author and culture critic Brandon Taylor about his latest novel, The Late Americans. The book is set in Iowa City and follows several characters pursuing love, ...

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, ...